Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) from a sell rating to a hold rating in a research report sent to investors on Sunday.

Other analysts have also issued reports about the stock. BTIG Research initiated coverage on shares of Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. Wedbush restated an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA traded down $0.13 during trading on Friday, hitting $11.63. The company had a trading volume of 105,605 shares, compared to its average volume of 219,325. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The business's 50-day moving average is $10.88 and its 200 day moving average is $12.63. The company has a market cap of $435.43 million, a P/E ratio of -2.58 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. On average, research analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. acquired a new position in shares of Oruka Therapeutics in the fourth quarter worth $303,000. Vanguard Group Inc. grew its stake in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after purchasing an additional 1,572,853 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $54,000. Wellington Management Group LLP increased its position in Oruka Therapeutics by 15.8% in the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after purchasing an additional 12,952 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Oruka Therapeutics by 2,348.6% during the 4th quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock worth $6,643,000 after purchasing an additional 328,434 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.